Cell-cleavable protecting groups often enhance cellulard elivery of species that are charged at physiological pH. Although severalp hosphonate protecting groups have achievedc linical success, it remains difficult to use these prodrugs in live cells to clarify biologicalm echanisms. Here, we present as trategy that uses a7 -methoxycoumarin-3-carboxylic acid ester as a fluorescent protecting group. This strategy was applied to synthesis of an (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP)a naloguet oa ssess cellularu ptake and human Vg9Vd2T cell activation. The fluorescent ester displayed low cellular toxicity (IC 50 > 100 mm)a nd strong Tcell activation (EC 50 = 0.018 mm)r elative to the unprotecteda nion (EC 50 = 23 mm). The coumarin-derived analogue allowed no-wash analysis of biological deprotection, which revealed rapid internalization of the prodrug. These results demonstrate that fluorescent groups can be applied both as functional drug delivery tools and useful biological probesofd rug uptake.
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Av ariety of drugs and other biologically interesting molecules contain phosphate or phosphonate substructures. [1] However, the negative charge that such compounds bear at physiological pH frequently acts as ab arriert oc ellular entry. [2] As such, development of cell-cleavable protecting groups that increase in vivo absorption is of great interest, with severalp hosphonate prodrugs recently achievingc linicals tatus. [3] Although cell-cleavable phosphoester [4] and phosphonamidate [5] protecting groups effectively increase cellular uptake, [6] it remains challenging to use thesec ompounds to assess biological mechanisms in real time because concentrations of compoundsi nl ive cells and their uptake rates cannot be readily assessed.
The small isoprenoid (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (1,H MBPP, Scheme 1) is am etabolic intermediate found in bacteria ando ther microorganisms. [7] HMBPP synthesis is required for bacterial growth [8] and also functions as ap otent pathogen-associated molecular pattern (PAMP) that stimulates an immune responsef rom human Vg9Vd2Tcells. [9] However, the mechanisms of HMBPP immunostimulation are currently at opic of intense debate, [10] and novel activators of Vg9Vd2T cells are desirable. [11] Therefore, development of HMBPP analogues that can contributet oa nu nderstanding of its immunostimulatory mechanism is warranted. [12] Here, we present ap H-sensitive,f luorescent, cell-cleavable phosphonate protecting group, the oxymethyl ester of 7-methoxycoumarin-3-carboxylic acid, to effectively quantify cellular uptake of ap hosphonate HMBPP analogue. Compounds containingt his group displayp otent activation of Vg9Vd2Tcells. Moreover,t his reporter might also provideameans by which cellular uptake of av ariety of phosphate and phosphonate drugs can be readily assessed with some precision.
The initial goal of this synthetic effort was to generate afluorescent prodrug. We applied the commonly used [3] non-fluorescent pivaloyloxymethyl (POM) [13] protecting group to both phosphonates [14] and bisphosphonates [15] and observeds trong gains in cellular potency,b ut lacked ways to easily quantify uptake in live cells. Here, we focused on ad erivative of the HMBPP analogue (E)-4-hydroxy-3-methyl-but-2-enyl phosphonate (2,C -HMBP). We viewed C-HMBP as an ideal molecule to use in this regard because:1 )ith as strong biological activity in as ystem that requires intracellular delivery;2 )itd isplays only weak cellular toxicity;3 )the mechanism(s) of action of its butyrophilin binding partner,B TN3A1,r emainu nclear;a nd, 4) POM-protected analogues 3 and 4 already werea vailable for use as biological controls. Thus, we would be readily able to assess changes in potency/toxicity of the protecting strategy. Furthermore, in contrastt oo ther phosphonates that require full deprotection for biological activity,t his compound is biologicallya ctive as the monoacid mono methyl ester.T herefore, rates of monohydrolysiso fv aried protecting strategies can be directly compared in cellular assays without the complexities of dihydrolysis.
The synthetic sequence (Scheme 2) began with preparation of 7-methoxycoumarin-3-carboxylic acid (5)b yt he known condensation of 2-hydroxy-4-methoxybenzaldehyde with Meldrum's acid. [16] This carboxylic acidw as treated withb ase and chloromethyl chlorosulfate, accordingt ot he procedure of Graham et al., [17] to obtain chloromethyl ester 6.T od etermine if this coumarin derivativewould be cleaved within ac ell to release ap hosphoantigen, we prepared ad erivative of the phosphonate 7,w hich we have found does not itself stimulate Vg9Vd2T cells. [14] To obtain the desired derivative,d imethyl ester 7 was treated with one equivalent of DABCO to obtain the mono ester mono salt 8. [18] This salt was allowed to react with the chloromethyl ester 6 in the presence of NaI, conditions intended to form the more reactive iodomethyle ster in situ. In refluxing acetonitrile, this led to formation of the desired mixed ester 9 in reasonable yield. Compound 9 was fluorescent,a se xpected, and was readily detected with maximum excitation at 355 nm and emission at 405. Therefore, it was examined in av ariety of biological experiments to determine if it would function asaprodrug.
We determined the activity of compound 9 in af unctional assay fori ts ability to stimulate proliferationo fp rimary human Vg9Vd2T cells (Figure 1 ). Peripheral blood mononuclear cells (PBMCs) were treated with test compounds. In these assays, compound 9 was expected to undergo cellular metabolism, leadingt oi ntracellular release of the carboxylic acid 5 and the biologically active compound 8 ( Figure S1 in the Supporting Information). Compound 4 was used as ac ontrol, because it too would be expected to deliver active compound 8 with similar stoichiometry.B oth compounds 4 and 9 did function as Vg9Vd2Tcell agonists, causing al arge expansion of the population of cells that expressb oth CD3 and the Vg9Vd2T cell receptor (Figure 2A ). This is ak ey finding, because it demonstrates that the coumarin-derived protecting group can effectively deliver ap hosphonate payload, resulting in biological activity.
The maximal agonist activity (observeda t1mm)o fc ompound 9 was not statistically different from that of POM analogue 4 ( Figure 1B )i nc ells from the same donors. Doseresponse curves ( Figure 1C )d etermined that compound 9 displays an EC 50 of 0.018 mm,w hereas compound 8 displays an EC 50 of 23 mm.T herefore, the coumarin-carboxylate oxymethyl ester (CCOM) strategy offered a1 300-fold increasei na ctivity. The potencyo fc ompound 9 compares favorably to the EC 50 value of 0.50 mm that we obtainedp reviously for compound 4 (Table S1 ), although availability of these primaryh uman cells dictated that the current set of compounds be tested in cells from differentd onors than those used for earlierc ompounds. This data shows minimal differences between the CCOM and POM protecting groups of am atched pair of compounds, suggesting thatt he CCOM protecting group has similarp rodrug Compound 9 is ap otent Vg9Vd2Tcellagonist. A) PBMCs were stimulated with 9,and phenotyping was performed to quantify the percentages of cells expressing both the Vg9Vd2T CR and the pan Tcell marker CD3. Compound 9 was evaluated at ac oncentration (1 mm)p reviously shown to be maximal for compound 4.Dataisr epresentative of three independent experiments. B) Quantification of Vg9Vd2Tcell proliferation in response to compounds 4 and 9.C)Dose-response curve for compound 9. D) Induction of Vg9Vd2Tcell-mediated K562l ysis by compounds 4 or 9. Graphs represent the mean AE standard deviation, n = 3. Statisticalsignificance was determined by ANOVA, *: p < 0.05. Because the previous experimentsu tilized at hree-day exposure time, the assays might not have been sensitive enough to assess subtle differencesi nt he rates of phosphonate release. Therefore, we soughtt oa ssess the activity of the novel compounds in am odel of Tcell-mediated cytotoxicity,w hicho ccurred with as hortere xposure of just 2h (Figure1D). K562 cells that were pre-loaded with compounds 4 and 9 were able to trigger Vg9Vd2Tcell-mediated killing with similar efficacy.
The ideal prodrug protecting group would be nontoxic.W e expectedt hat to be the case for CCOM protection, as the activity of compound 9 in the Tcell proliferation assay was similar to that of POM compound 4.T oe stablish the effects of the CCOM protecting group on cell viability,w eevaluated growth inhibition in several cell lines. The carboxylic acid 5 alonew as nontoxic to K562, Daudi, RPMI-8226, and Jurkatc ells when they were exposed for 72 ha tc oncentrations up to 100 mm (Table S2) . Treatmento fK 562, Daudi,o rJ urkat cells with compounds 4 or 9 displayed no toxicity.D ifferencesw ere observed between compounds 4 and 9 only in RPMI-8226 cells at100 mm treatment ( Figure S2 ), much highert han the EC 50 values for stimulation of Vg9Vd2Tcells.
We next determined whether compound 9 would be auseful probe with which to determine rates of biological deprotection (Figure 2 ). Compounds 5 and 9 were readily detected by spectrofluorimetry in aqueous solutions.I mportantly,t he fluorescence intensityo fc ompound 5,b ut not prodrug 9,w as strongly dependentu pon the pH of the solution ( Figure 2A) , correlating with the expectedp rotonation status of the carboxylic acid in compound 5.I nw ater,t he intensity of 5 was less than 10 %o fi ts intensity at pH 3( Figure 2A) . Therefore, the CCOM prodrugs would be expectedt or apidlyl ose fluorescence intensity during metabolism at neutralp H, as the carboxylate is released from the prodrug and remainsi nt he deprotonated form.
We then adapted this assay to a3 84-well-plate format for use in ap late readere quipped with a3 55/40 nm excitation filter and a4 05/10 nm emission filter.A se xpected, the fluorescence intensity of 9 in phosphate-buffered saline (PBS) was much higher than that of 5 in PBS( Figure 2B) . Additionally,the fluorescenceo fc ompound 5 was furtherr educed when incubated in human plasma ( Figure S3 ). The loss of fluorescencei n plasma was not due to metabolism of the coumarin, as analysis by thin-layer chromatography (TLC) of plasma extracts under UV light confirmed that this group had not been destroyed, and furthers pectral analysisd id not identify as hift in the excitation or emission spectra.T herefore, the esterasemediated hydrolysis of 9 could be readily assessed by quantification of the two-step (releasef ollowed by quenching) loss of fluorescencef ollowing exposure to various biological matrices. Importantly,t his measurement could be done directly in a single plate without washing or furtherassays teps.
In the presence of human plasma, the concentration of compound 9 decreased over time ( Figure 2C )w ith second-order kinetics. The half-life was determined to be 6min in this assay, whereas the half-life of compound 9 in PBS at 37 8Cw as 26 h. In order to confirmt hat the loss of fluorescenceo f9 was due to hydrolysis of the CCOM-phosphonate ester and not fluorescence destruction, we extracted the end products and analyzed by TLC ( Figure 2D ). As expected, compound 9 was fully hydrolyzed to yield the free carboxylic acid in at ime-dependent manner.L oss of the prodrug occurreda tt he same time as the appearance of the free acid. The enzymatic release occurred with ah alf-life of 7.8 min in this assay.T he rate of hydrolysis in plasma is similart os ome bis-POM compounds. [19] This is an important finding, because it indicates that the presence of ab icyclic aromatic group does not prevent enzymatic hydrolysis of the phosphonate ester,n or does it permit rapid non-enzymatic degradation.
We used compound 9 to examine internalization into K562 cells in PBS. No loss of fluorescence was observed in PBS (Figure 2E) . Surprisingly, K562 cells could rapidly decrease the extracellularc oncentration ( Figure 2F ). This occurredw ith firstorder kinetics and ah alf-life of 55 min. Although our current data cannot rule out the possibility that the K562 cellssecreted an esterase, we believe these findings demonstrate the striking efficacy of phosphonate ester prodrugs to deliver their payload. Within hours, effectively all of the drug can pass into the cells.
In conclusion, we report the synthesis of an ovel fluorescent pH-dependentc ell-cleavable protecting group and its application to an HMBPP analogue. These resultss how that bulky www.chembiochem.org fluorescent systems can be tolerated by cellular esterases without loss of activity or generation of toxicity relative to the commonly used POM protection. Fluorescent prodrugs [20] are useful to detect the speed of cellularu ptakei nawayt hat is much faster and requires significantly smaller volumes of cells and materials relative to radiolabeling [21] or HPLC [22] approaches, making them amenable to high-throughput applications. Although our current resultsa re focused on release of the monoacid form, we predict that ap arallel strategy could be used to modify phosphonates to releaset he diacid formo f compounds that requiref ull deprotection for biological activity.F urther development of fluorescentp rodrugs along these lines is underway and will be reported in due course.
Experimental Section
Biological procedures: Whole blood from anonymous healthy donors collected under an IRB-approved signed consent form was purchased from Research Blood Components (Boston, MA). Cells were expanded from human PBMCs in fresh Tcell medium (RPMI-1640, 10 %h eat-inactivated FBS, 1 HEPES, pyruvate, non-essential amino acids, penicillin/streptomycin, b-mercaptoethanol) and added to six-well plates. Cells were stimulated with test compounds for three days. Cells were washed twice, then cultured for another 11 days after compound removal. Human interleukin 2 (5 ng mL À1 )w as added as as upplement every three days. Experiments were performed at least three times independently by using at least two different blood donors. In lysis assays, cells that had been expanded with 10 mm HMBPP and purified by negative selection (Miltenyi)w ere used.
